NCT04471818View on ClinicalTrials.gov

Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

June 1, 2023

Study Completion Date

July 30, 2023

Conditions
Major Depressive DisorderAdvanced Cancer
Interventions
DRUG

Ketamine

Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study

OTHER

Placebo

Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study

Trial Locations (1)

Unknown

Instituto Nacional de Cancerología (INCan), Mexico City

All Listed Sponsors
lead

Instituto Nacional de Cancerologia de Mexico

OTHER

NCT04471818 - Ketamine or Placebo in Patients With Major Depression and Advanced Cancer | Biotech Hunter | Biotech Hunter